Then, we tested if this ASO-mediated inhibition of the BCL2L1 pro-apoptotic variant following pladienolide B treatment was able to reduce the antitumor effect of pladienolide B on GBM growth using a proliferation assay. Here, BCL2L1 is linked to glioblastoma.